Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Bakouny Z, Paciotti M, Schmidt AL, Lipsitz SR, Choueiri TK, Trinh Q. Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic. JAMA Oncol. 2021;7(3):458–460. doi:10.1001/jamaoncol.2020.7600
Oncology patient care may be disrupted secondary to coronavirus disease 2019 (COVID-19) through delays in diagnostic investigations and surgical procedures, as well as delayed cancer diagnoses because of reduced cancer screening. This study assesses the number of patients undergoing cancer screening tests and of ensuing cancer diagnoses during the COVID-19 pandemic in the largest health care system in the northeastern United States, Massachusetts General Brigham.
This study comprised four 3-month periods. One period, during the first peak of the pandemic in the New England area of the United States (from March 2 to June 2, 2020),1 was compared with 3 control periods before and after the main study period (the preceding 3 months from December 1, 2019, to March 2, 2020; the same 3 months in the preceding year from March 2 to June 2, 2019; and the 3 months after the main study period from June 3 to September 3, 2020). The percentage decrease in screening tests and in diagnoses during the pandemic period compared with each of the control periods was computed as percentage decrease = (Npandemic − Ncontrol)/Ncontrol. The 95% CIs were computed using the Clopper-Pearson method using the DescTools package in R. All analyses were performed using R, version 3.6.1 (R Foundation for Statistical Computing) (eMethods in the Supplement). Ethical approval for the study was provided by Brigham and Women’s Hospital prior to commencement of data analysis, including a waiver of the requirement for individual patient consent given the retrospective and noninterventional nature of the research.
Create a personal account or sign in to: